Tryptophan metabolism in health and disease
C Xue, G Li, Q Zheng, X Gu, Q Shi, Y Su, Q Chu… - Cell Metabolism, 2023 - cell.com
Tryptophan (Trp) metabolism primarily involves the kynurenine, 5-hydroxytryptamine, and
indole pathways. A variety of bioactive compounds produced via Trp metabolism can …
indole pathways. A variety of bioactive compounds produced via Trp metabolism can …
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy
M Ala - European Journal of Pharmacology, 2021 - Elsevier
Abstract Treatment of cancers has always been a challenge for physicians. Typically,
several groups of anti-cancer medications are needed for effective management of an …
several groups of anti-cancer medications are needed for effective management of an …
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape …
C Krupka, P Kufer, R Kischel, G Zugmaier… - Leukemia, 2016 - nature.com
Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells. We
tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute …
tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute …
[HTML][HTML] Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis
PA Zunszain, C Anacker, A Cattaneo… - …, 2012 - nature.com
Increased inflammation and reduced neurogenesis have been associated with the
pathophysiology of major depression. Here, we show for the first time how IL-1β, a pro …
pathophysiology of major depression. Here, we show for the first time how IL-1β, a pro …
Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets
M Stahl, AD Goldberg - Current oncology reports, 2019 - Springer
Abstract Purpose of Review Immune checkpoint therapy has dramatically changed the
therapeutic landscape of solid malignancies. Here, we review the scientific rationale and …
therapeutic landscape of solid malignancies. Here, we review the scientific rationale and …
[HTML][HTML] Indoleamine 2, 3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
V Folgiero, BM Goffredo, P Filippini, R Masetti… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Microenvironmental factors contribute to the immune dysfunction characterizing acute
myeloid leukemia (AML). Indoleamine 2, 3-dioxygenase 1 (IDO1) is an interferon (IFN)-γ …
myeloid leukemia (AML). Indoleamine 2, 3-dioxygenase 1 (IDO1) is an interferon (IFN)-γ …
Harnessing the immune system in acute myeloid leukaemia
Acute myeloid leukaemia (AML) is an aggressive blood cancer caused by the proliferation of
immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction …
immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction …
Interferon‐induced programmed death‐ligand 1 (PD‐L 1/B 7‐H 1) expression increases on human acute myeloid leukemia blast cells during treatment
H Krönig, L Kremmler, B Haller… - European journal of …, 2014 - Wiley Online Library
Introduction While current treatment for acute myeloid leukemia is characterized by high
response rates, patients' long‐term outcome is still disappointing, due to frequent relapse …
response rates, patients' long‐term outcome is still disappointing, due to frequent relapse …
[HTML][HTML] Mesenchymal stem and progenitor cells in normal and dysplastic hematopoiesis—masters of survival and clonality?
L Pleyer, P Valent, R Greil - International journal of molecular sciences, 2016 - mdpi.com
Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders that
have the capacity to progress to acute myeloid leukemia (AML). Accumulating evidence …
have the capacity to progress to acute myeloid leukemia (AML). Accumulating evidence …
Metabolic regulation of the bone marrow microenvironment in leukemia
B Xu, R Hu, Z Liang, T Chen, J Chen, Y Hu, Y Jiang… - Blood Reviews, 2021 - Elsevier
Most leukemia patients experience little benefit from immunotherapy, in part due to the
immunosuppressive bone marrow microenvironment. Various metabolic mechanisms …
immunosuppressive bone marrow microenvironment. Various metabolic mechanisms …